SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Kymera Therapeutics Sets Nov. 23 Date for KT-621 Trial Results

Kymera Therapeutics says it will announce results from the Phase 2b BROADEN2 atopic dermatitis trial on Nov. 23, 2026.

KYMR

Related stories